



**Maryland Prescription Drug Affordability Board  
Meeting Agenda**

Virtual

March 24, 2025 — 2:00 p.m.

- I. Call Meeting to Order
- II. Minutes—February 26, 2025 Meeting and January 27, 2025 Closed Session
- III. Opportunity for Public Comment<sup>1</sup>
- IV. Cost Review Study— Farxiga and Jardiance
  - a. Staff Presentation—Overview of Process
  - b. Closed Session—To Consider and Discuss Confidential, Trade Secret and Proprietary Information, under GP § 3-305(b)(13) and HG 21-2c-03(e)(1)(iv) (Farxiga, Jardiance); and to Consult with Counsel and Receive Legal Advice Regarding Proposed Regulations, under GP § 3-305(b)(7).
- V. Regulations

Proposed Amendments to COMAR 14.01.01.01 (Definitions); new COMAR 14.01.01.06 (Hearing Procedures); new COMAR 14.01.05 (Policy Review, Final Action, Upper Payment Limits)
- VI. Administrative Update
- VII. Chair’s Update
- VIII. Adjournment

Please register for the Prescription Drug Affordability Board Meeting on March 24, 2025 at 2:00 PM ET at [pdab.maryland.gov](http://pdab.maryland.gov). After registering, you will receive a confirmation email containing information about how to join the webinar.

Next PDAB Meeting: The Board’s next regularly scheduled meeting will be on May 19, 2025. Information for this meeting will be published on the PDAB website at [pdab.maryland.gov](http://pdab.maryland.gov).

---

<sup>1</sup> The public may submit written comments on the Board’s pending decisions, or general comments regarding the Board’s work, to [comments.pdab@maryland.gov](mailto:comments.pdab@maryland.gov). For more information on presenting comments during the meeting, please visit the Board Meetings page at the PDAB’s website.